Minerva Neurosciences Inc (NERV)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$2.57+9.36%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · NERV
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name is on a run of consecutive earnings misses and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
NERV — earnings miss
Dated 2026-08-07
of this Current Report on Form 8-K, including the accompanying Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filling.
Why it matters: The trial needs 380 patients at about 40 sites. Slow enrollment could put the planned 2H 2027 data at risk.
Worry ifA company update reports enrollment is on track for 380 patients and keeps topline data in 2H 2027.
Less concerning ifA company update reports enrollment delays or moves the Phase A data date beyond 2H 2027.
Why it matters: The next report can show whether trial work is on track and how fast cash is being used. These are key near-term tests for Minerva.
Watch forThe report says C19 enrollment is on track and cash remains at or above $75 million.
Also watch forThe report cites C19 delays or cash below $60 million.
Why it matters: This test will show if roluperidone eases negative symptoms more than placebo. It is the trial's main test of how well it works.
Watch forThe Phase A readout meets the primary endpoint for change in the Marder Negative Symptoms Factor Score.
Also watch forThe Phase A readout misses the primary endpoint or shows no clear benefit over placebo.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$294 on $10,000 · ±2.9% | How much price usually moves either way. |
| Bad day | $937 loss on $10,000 · 9.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,274 loss on $10,000 · 72.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.